Abstract
Liver fibrosis refers to the excessive buildup of scar tissue in the liver, which can lead to cirrhosis and hepatocellular carcinoma. It often presents with a hypoxic hepatic microenvironment and elevated oxidative stress. In this work, we present a hybrid Exosome-Bilosome Oxygen-encapsulating Nanobubble (EBON) with antifibrotic properties that has the potential to protect the liver from localized hypoxia and oxidative stress-induced hepatic damage. Grapefruit-derived exosome-like vesicles utilized here may contribute to the therapeutic potential of the EBON formulation by delivering antioxidant, anti-inflammatory, and antifibrotic cargo, alongside oxygen. EBON has a sub-50 nm size with an oxygen loading capacity of about 50 mg/L and a shelf life of half a year. EBON has demonstrated excellent protection against cellular hypoxia, reactive oxygen species, and superoxide-induced damage in LX-2 and HepG2 cell lines. Additionally, EBON has shown a significant antifibrotic effect in palmitic acid and oleic acid-induced lipotoxicity and oxidative stress-mediated fibrosis model in LX-2/HepG2 multilineage hepatic spheroids. RT-qPCR results confirmed suppression of hypoxia (HIF-1α, VEGF-A), oxidative stress (Nrf2), and pro-fibrotic signaling (α-SMA, TGF-β1, and COL1A1) associated genes in the in vitro hepatic spheroid model. Additionally, the safety profile of EBON has been established in a 14-day murine oral gavage model, validating short-term oral tolerability. We propose that the hybrid Exosome-Bilosome Oxygen encapsulating Nanobubble reported here is a proof-of-concept platform with antifibrotic potential for addressing hypoxia associated with liver fibrosis.
Funding Information
  • Graduate Program in Physics at UNIFAL-MG (1R21EY035371-01)
  • Graduate Program in Physics at UNIFAL-MG (2236857)

This publication has 41 references indexed in Scilit: